Clinical Research Division, Fred Hutch
Dr. Paul Carpenter leads research and clinical care teams that support bone marrow and stem cell transplant survivors long after they finish initial treatment. As director of the world-class post-transplant Adult Clinical Care Long-Term Follow-Up Program, known as the LTFU, Dr. Carpenter and his colleagues are helping transplant survivors and their primary care physicians manage post-treatment complications as patients recover and resume their lives. The LTFU also serves as a model for the training of transplant physicians. In his own research, Dr. Carpenter is developing better treatments for graft-vs.-host disease. GVHD is a common complication of bone marrow transplantation that can cause serious illness and even death. In GVHD, donor immune cells attack the patient’s healthy cells. Dr. Carpenter leads clinical trials of new therapies for acute and chronic GVHD. He is studying new ways to overcome long-term complications of GVHD treatments and prevent relapse after transplant.
Medical Director, Long-Term Follow-Up Clinical Service
Fred Hutchinson Cancer Center
Professor, Division of Pediatrics
University of Washington School of Medicine
BSc, Medicine, University of Sydney, Australia
MBBS, Medicine and Surgery, University of Sydney, Australia
Dr. Carpenter is participating in a multi-site trial that will collect and analyze samples from pediatric HCT patients in order to validate biomarkers of acute and chronic GVHD. Enrollment recently completed on a phase I/II clinical trial to determine if giving patients nilotinib 100 days after HCT is effective in reducing relapse in patients with Philadelphia chromosome-positive leukemias. Data analysis is beginning on a national multicenter trial he is leading that compared two chronic graft-versus-host disease drug regimens.
The Media Relations team at Fred Hutch is available to assist members of the news media who would like to arrange interviews with faculty.
Email firstname.lastname@example.org or call 206.667.2210